Yong-Guang Tao

Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review

Abstract More than a decade after ferroptosis was first defined, no agent designed to exploit it has won clinical approval for cancer. We argue that the bottleneck has shifted from mechanism to translation: unsatisfactory pharmacokinetics with unreliable intratumoral accumulation; resistance arising from single-pathway...